Human Growth Hormone Market

Human Growth Hormone Market by Applications (Growth Hormone Deficiency [Adult Growth Hormone Deficiency, and Pediatric Growth Hormone Deficiency], Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1868
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 216
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global human growth hormone market size was valued USD 5.9 billion in 2020 and is projected to reach USD 10.84 billion by 2028, expanding at a CAGR of 8.4 % during the forecast period, 2021–2028. The growth of the market is attributed to the factors such as increasing industry players’ investments in R&D activities, the presence of a strong pipeline, and expanding government initiatives.

Human Growth Hormone Market

Human growth hormone (hGH), also known as somatotropin, is a peptide hormone that is vital for human development, as it stimulates growth, cell reproduction, and cell regeneration. In humans, growth hormone (GH) insufficiency is caused by the failure of pituitary gland to generate enough hGH. In humans, this deficit is addressed by subcutaneous injections of recombinant hGH. Growth hormone insufficiency in humans can be caused by a variety of genetic illnesses, including Prader-Willi syndrome and Turner syndrome, which can result in delayed puberty and shorter-than-average height.

According to data released by the American Academy of Pediatrics, growth hormone insufficiency is a rare illness that affects less than one in 10,000 children in the US. hGH is being abused by bodybuilders and sportsmen as an anti-aging treatment and as a performance-enhancing anabolic substance. However, according to the USFDA, hGH is a regulated chemical that has not been licensed for anti-aging or performance-enhancing purposes.

International Children's Growth Awareness Day is observed every year by the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a non-profit charitable organization based in the US, to raise awareness about the early detection and treatment of growth hormone disorders in humans, particularly children. According to UPMC Children's Hospital of Pittsburgh. Knee, hip, or other joint discomfort, allergic reactions, such as redness, swelling, or hives, and increase in the blood sugar levels are all possible adverse effects of GH therapy,

Market Trends, Drivers, Restraints, and Opportunities

  • Various government and private organizations initiatives to raise awareness about GH deficiency and human growth hormone treatment are driving the market growth.
  • High cost of therapies can hinder the market growth.
  • Rapid development of new novel recombinant human growth hormones is estimated to spur the market expansion in the coming years.

Scope of the Report

The report on the global human growth hormone market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Human Growth Hormone Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Applications (Growth Hormone Deficiency [Adult Growth Hormone Deficiency, and Pediatric Growth Hormone Deficiency], Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, and Others) and Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novo Nordisk A/S, Pfizer, Inc, Eli Lilly and Company, Sandoz International GmbH (Novartis AG), Merck KGaA, Genentech, Inc. (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd., and Ipsen

Human Growth Hormone Market Segment Insights

Growth Hormone Deficiency segment is projected to account for a key market share

Based on applications, the market is segmented into growth hormone deficiency, Turner syndrome, idiopathic short stature, Prader Willi syndrome, small for gestational age, and others. The growth hormone deficiency segment is further divided into adult growth hormone deficiency and pediatric growth hormone deficiency. The growth hormone deficiency segment is expected to account for a key market share during the forecast period owing to the early detection and treatment of GH deficiency in people, as well as the introduction of new medications into the market. For instance, Ascendis Pharma A/S gained Orphan Designation from the European Commission (EC) in October 2018 for TransCon hGH, an experimental long-acting GH medication for humans, recommended for the treatment of pediatric GH deficiency. Similarly, Ferring Pharmaceuticals Inc. got USFDA approval in January 2018 for Zomacton (somatropin), a novel recombinant hGH intended for the treatment of adults with GH insufficiency.

Adult GH deficiency and pediatric GH deficiency are the two types of GH deficiency, with the latter expected to dominate the market during the forecast period due to the growing number of pipeline medications. For instance, in October 2019, Pfizer Inc. and its partner OPKO Health Inc., stated that their Phase III research of Somatrogon in pre-pubertal children with hGH met its primary endpoint of non-inferiority to daily somatropin.

The Turner syndrome segment is anticipated to expand at a rapid pace during the forecast period owing to increasing public and commercial sector initiatives to raise awareness about early detection and treatment of Turner syndrome. Every year in February, non-profit organizations such as the Turner Syndrome Support Society in the UK, the Turner Syndrome Society of the US, and the Turner Syndrome Foundation celebrate "Turner Syndrome Awareness Month" and launch a nationwide campaign to raise awareness about the condition.

Human Growth Hormone Market

Online pharmacy segment is anticipated to expand at a substantial CAGR

On the basis of distribution channels, the human growth hormone market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. The online pharmacies segment is expected to expand at a rapid pace during the forecast period owing to the increasing penetration of pharmacies in regions such as North America and Europe. Additionally, growing preference for online pharmacies in emerging economies such as India and China is expected to drive the segment growth. In 2019, the hospital pharmacies segment accounted for a major market share. According to the Children's Hospital of Philadelphia (CHOP), prescriptions for growth hormone have climbed from 5.1 patients per 10,000 beneficiaries in 2001 to 14.6 patients per 10,000 beneficiaries in 2016.

Human Growth Hormone Market

Asia Pacific is anticipated to dominate the market

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period. Key companies aim to gain a significant market share in Asia Pacific, especially in Japan and China. For instance, in March 2017, Novo Nordisk A/S, a Denmark-based pharmaceutical company, began a phase III clinical trial in Japan for its hGH somapacitan, which is used to treat adult growth hormone insufficiency.  

North America is anticipated to account for a significant market share owing to the presence of favorable reimbursement scenarios, established healthcare infrastructure, major government initiatives, and rising healthcare awareness. Furthermore, increasing access to novel medications due to the presence of important competitors in the region is driving the market growth in the region. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are some of the leading US-based competitors in the region, offering a wide range of human GH medicines.

Human Growth Hormone Market

 

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Growth Hormone Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Human Growth Hormone Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Human Growth Hormone Market - Supply Chain
  4.5. Global Human Growth Hormone Market Forecast
     4.5.1. Human Growth Hormone Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Human Growth Hormone Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Human Growth Hormone Market Absolute $ Opportunity
5. Global Human Growth Hormone Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Human Growth Hormone Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Human Growth Hormone Demand Share Forecast, 2019-2026
6. North America Human Growth Hormone Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Human Growth Hormone Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Human Growth Hormone Demand Share Forecast, 2019-2026
7. Latin America Human Growth Hormone Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Human Growth Hormone Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Human Growth Hormone Demand Share Forecast, 2019-2026
8. Europe Human Growth Hormone Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Human Growth Hormone Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Human Growth Hormone Demand Share Forecast, 2019-2026
9. Asia Pacific Human Growth Hormone Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Human Growth Hormone Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Human Growth Hormone Demand Share Forecast, 2019-2026
10. Middle East & Africa Human Growth Hormone Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Human Growth Hormone Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Human Growth Hormone Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Human Growth Hormone Market: Market Share Analysis
  11.2. Human Growth Hormone Distributors and Customers
  11.3. Human Growth Hormone Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Novo Nordisk A/S Pfizer, Inc. Eli Lilly and Company Sandoz International GmbH (Novartis AG) Merck KGaA Genentech, Inc (Roche)  

Segments Covered in the Report

The global human growth hormone market has been segmented on the basis of

Applications

  • Growth Hormone Deficiency
    • Adult Growth Hormone Deficiency
    • Pediatric Growth Hormone Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Small for Gestational Age
  • Others

Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Sandoz International GmbH (Novartis AG)
  • Merck KGaA
  • Genentech, Inc (Roche)
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries, Ltd
  • Ipsen.

Key players competing in the human growth hormone market include Novo Nordisk A/S, Pfizer, Inc, Eli Lilly and Company, Sandoz International GmbH (Novartis AG), Merck KGaA, Genentech, Inc. (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd., and Ipsen.

Mergers, collaborations, and acquisitions are common strategies adopted by big industry players to increase their geographic reach. For instance, in October 2018, Novo Nordisk and Strongbridge Biopharma agreed to buy MACRILEN's rights in the US and Canada. MACRILEN (macimorelin) is the first and only oral medicine licenced by the Food and Drug Administration (FDA) for the diagnosis of adult growth hormone insufficiency.

In September 2018, Novo Nordisk reported Phase II clinical trial data for Somapacitan, an experimental growth hormone medication indicated for the treatment of juvenile growth hormone insufficiency.

In May 2019, Ascendis Pharma A/S released results from a Phase III clinical trial of their TransCon hGH, which is indicated for pediatric growth hormone insufficiency. Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences are among the prominent companies that are active in R&D activities for the development of innovative hGH therapy.

Human Growth Hormone Market

Buy Report